761440-06-6 Usage
Uses
Used in Pharmaceutical Industry:
1H-Isoindol-1-one,7-amino-2,3-dihydro-2-methyl-(9CI) is used as a pharmaceutical precursor for the development of potential drug candidates due to its unique structure and properties that contribute to the creation of biologically active compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Isoindol-1-one,7-amino-2,3-dihydro-2-methyl-(9CI) is utilized as an intermediate in the synthesis of various compounds with therapeutic potential, enhancing the discovery and design of new medications.
Used in Organic Synthesis:
1H-Isoindol-1-one,7-amino-2,3-dihydro-2-methyl-(9CI) is employed as a versatile building block in organic synthesis for the production of complex molecules and chemical compounds, facilitating the creation of novel substances with specific applications.
Check Digit Verification of cas no
The CAS Registry Mumber 761440-06-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,1,4,4 and 0 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 761440-06:
(8*7)+(7*6)+(6*1)+(5*4)+(4*4)+(3*0)+(2*0)+(1*6)=146
146 % 10 = 6
So 761440-06-6 is a valid CAS Registry Number.
761440-06-6Relevant articles and documents
Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype
Walter, Anne,Chaikuad, Apirat,Helmer, Renate,Loa?c, Nadège,Preu, Lutz,Ott, Ingo,Knapp, Stefan,Meijer, Laurent,Kunick, Conrad
, (2018/05/22)
Cdc2-like kinases (CLKs) represent a family of serine-threonine kinases involved in the regulation of splicing by phosphorylation of SR-proteins and other splicing factors. Although compounds acting against CLKs have been described, only a few show select
MACROCYCLIC KINASE INHIBITORS
-
, (2012/06/16)
Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.
PYRIMIDINE DERIVATIVES
-
Page/Page column 83; 84, (2008/06/13)
Novel pyrimidine derivatives of formula (I) to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
